CTRI/2020/06/025899尚未招募1 期
COMPARATIVE EVALUATION OF THE EFFICACY OF MEDOHAR VATI IN DYSLIPIDEMIA (MEDOROGA)
Patanjali Research Institute Haridwar0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Participant is not on a statin or other lipid-modifying therapy.
- •Plasma levels >=200 mg/dL for TC, >=130 mg/dL for LDL-C, <40 mg/dL for HDL-C, and >=150 mg/dL and (b) serum CRP >5 mg/dL.
排除标准
- •oFemale participant of reproductive potential.
- •oParticipant is pregnant, breastfeeding, or expecting to conceive during the study.
- •oParticipant has history of cancer within 5 years of study (except certain types of skin and cervical cancer).
- •oParticipant is a user of recreational or illicit drugs or has a recent history of drug and/or alcohol abuse.
- •oParticipant has donated or received blood within 8 weeks of study start or intends to give/receive blood during the study.
- •oParticipant consumes more than 3 alcoholic drinks per day or more than 14 alcoholic drinks per week.
- •oParticipant is currently experiencing menopausal hot flashes.
- •oParticipant currently engages in vigorous exercise or an aggressive diet regimen.
- •oParticipant is at high risk for heart conditions.
- •oParticipant has Type 1 or Type 2 diabetes mellitus.
- •oParticipant has poorly controlled cardiac arrhythmias.
- •oParticipant has a history of stroke or other hemorrhage.
- •oParticipant has poorly controlled high blood pressure.
- •oParticipant has a thyroid condition or other endocrine/metabolic disease that would affect serum lipids.
- •oParticipant has a disease of the kidney or liver.
- •oParticipant has an ulcer within 3 months of screening.
- •oParticipant is Human Immunodeficiency Virus (HIV) positive.
- •oParticipant is taking cyclical hormonal contraceptives or non-continuous hormone replacement therapy.
- •oParticipant is taking or has taken an Organic Anion Transporter (OAT1/3) inhibitor/substrate within 3 days of screening.
- •oParticipant has taken an anti-obesity medication within 3 months of screening.
- •oParticipant is taking coumarin.
- •oParticipant is taking Non-Steroidal Anti-inflammatory Drugs (NSAIDs) (acetaminophen and Cyclooxygenase-2 (COX-2) inhibitors are allowed).
- •oParticipant is taking more than 100 mg aspirin per day.
- •oParticipant is being treated with oral, intravenous, or injected corticosteroids or anabolic agents.
研究者
相似试验
尚未招募
3 期
To Compare The Three Routes Of Administeration Of Medopachak Yoga In Obesity (Sthoulya)CTRI/2024/07/071258Mahatma Gandhi Ayurveda College Hospital And Research Centre Salod Wardha
尚未招募
3 期
Ayurvedic treatment for ObesityCTRI/2022/03/041062Ch Brahm Prakash Ayurved Charak Sansthan
尚未招募
3 期
Medhya Rasayana versus Non Pharmacological Intervention in the Management of Gadget AddictioCTRI/2022/12/048638Dr Prasad Yewale
尚未招募
2 期
Effect of chanting Medha Sukta- Ritual hymns in academic performance of school childreCTRI/2020/01/022967Dr Sushmitha P
尚未招募
3 期
A clinical trial to study the effect of two drugs,medonihanthi yogam and suddha guggulu vati in patients with obesity.CTRI/2024/04/065498DrAshikaa K S